FDA Approval of Nivolumab for the First-Line Treatment of...

  • Main
  • 2017 / 01
  • FDA Approval of Nivolumab for the First-Line Treatment of...
Clinical Cancer Research 2017 / 01

FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

Beaver, Julia A., Theoret, Marc R., Mushti, Sirisha, He, Kun, Libeg, Meredith, Goldberg, Kirsten, Sridhara, Rajeshwari, McKee, Amy E., Keegan, Patricia, Pazdur, Richard
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-16-0714
Date:
January, 2017
File:
PDF, 212 KB
english, 2017
Conversion to is in progress
Conversion to is failed